Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT03226210
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 110 participants
- Registry
-
NCT03226210
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03226210. Randomized; single masking; primary purpose treatment. Start 2015-02-01 (actual); primary completion 2016-05-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- aspart insulin or lipro insulin
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical University
Record details
- Record id
cardio:ct-nct03226210- Content hash
eea665f5e5e5d58e78c9c674e19abcd4dbee70ca42d3c2471ea91499484ef4b2